Sutro Biopharma Inc

Sutro Biopharma Inc. engages in the drug discovery, development and manufacture of pharmaceutical products. It focuses on the next generation cancer and autoimmune therapeutics. The company was founded by James R. Swartz and Sutanto Widjaja on April 21, 2003 and is headquartered in South San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Sutro Biopharma, Inc. engages in the drug discovery, development and manufacture of pharmaceutical products. It focuses on the next generation cancer and autoimmune therapeutics. The company was founded by James R. Swartz and Sutanto Widjaja on April 21, 2003 and is headquartered in South San Francisco, CA.

The average of price targets set by Wall Street analysts indicates a potential upside of 294.8% in Sutro Biopharma, Inc. (STRO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Think Sutro Biopharma, Inc. (STRO) Could Surge 295%: Read This Before Placing a Bet

Sutro Biopharma, Inc. (STRO) delivered earnings and revenue surprises of 25.68% and 105.92%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Sutro Biopharma, Inc. (STRO) Reports Q2 Loss, Tops Revenue Estimates

- Collaboration with Astellas on discovery and development of iADCs for up to three targets, includes an upfront payment of $90 million and $422.5 million in potential milestones per product candidate -

Sutro Biopharma Reports Second Quarter 2022 Financial Results, Business Highlights and Anticipated Milestones

SOUTH SAN FRANCISCO, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will present at the 2022 Wedbush PacGrow Healthcare Conference's panel discussion, “ADCs - Take Me to Your Tumor” on Wednesday, August 10, 2022, at 2:20 p.m. ET / 11:20 a.m. PT.

Sutro Biopharma to Present at the 2022 Wedbush PacGrow Healthcare Conference

SOUTH SAN FRANCISCO, Calif., July 26, 2022 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (“Sutro” or the “Company”) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that the first patient has been dosed in a Phase 1 study of an investigational candidate resulting from the collaboration between Sutro and Merck, known as MSD outside the United States and Canada, for the development of a novel cytokine derivative therapeutic for the treatment of cancer. As a result of this milestone, Sutro will receive a $10 million payment from Merck.

Sutro Biopharma Achieves “First in Human” Milestone in Cytokine Derivatives Collaboration with Merck

SOUTH SAN FRANCISCO, Calif., July 12, 2022 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (“Sutro” or the “Company”) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that management will host a virtual research forum in which it will unveil the next product candidate, discuss immunostimulatory ADCs (iADCs) as a novel modality, and highlight recent enhancement to its cell-free manufacturing platform.

Sutro Biopharma Announces Virtual Deep Dive Research Forum: Next-Gen Innovations in ADCs

Sutro Biopharma (STRO) inks a partnership and licensing deal with Astellas Pharma to discover and develop iADCs for cancer patients not responding to existing therapies.

Sutro Biopharma (STRO) Up 50% on Cancer Treatment Collaboration

Astellas Pharma Inc (OTC: ALPMF) and Sutro Biopharma Inc (NASDAQ: STRO) announced a strategic collaboration and licensing agreement focused on the discovery and development of immunostimulatory antibody-drug conjugates (iADC).  iADCs are a next-generation.

Sutro Biopharma Stock Surges On Cancer Treatment Pact

- iADCs are a next-generation modality for treating cancer and designed to boost anti-cancer activity, offering potential new options for patients who do not respond to existing cancer immunotherapies -

Astellas and Sutro Biopharma Announce Worldwide Strategic Collaboration to Advance Novel Immunostimulatory Antibody-Drug Conjugates (iADCs)

Vaxcyte

- iADCs are a next-generation modality for treating cancer and designed to boost anti-cancer activity, offering potential  new options for patients who do not respond to existing cancer immunotherapies - - Sutro will receive an upfront payment of US$90 million to develop iADCs for three biological targets and may be eligible to receive up to an additional US$422.5 million USD in development, regulatory and commercial milestones for each product candidate, plus royalties - TOKYO and SOUTH SAN FRANCISCO, Calif. , June 27, 2022 /PRNewswire/ --  Astellas Pharma Inc. (TSE: 4503), (President and CEO: Kenji Yasukawa, Ph.D.

Astellas and Sutro Biopharma Announce Worldwide Strategic Collaboration to Advance Novel Immunostimulatory Antibody-Drug Conjugates (iADCs)

Sutro Biopharma, Inc. (STRO) delivered earnings and revenue surprises of -6.33% and 48.64%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Sutro Biopharma, Inc. (STRO) Reports Q1 Loss, Misses Revenue Estimates

- Cash, cash equivalents and marketable securities totaled $192.1 million as of March 31, 2022, with projected cash runway into the second half of 2023 -

Sutro Biopharma Reports First Quarter 2022 Financial Results, Business Highlights, and Anticipated Milestones

Sutro Biopharma (STRO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Surprise Coming for Sutro Biopharma (STRO) This Earnings Season?

SOUTH SAN FRANCISCO, Calif. , April 8, 2022 /PRNewswire/ -- Sutro Biopharma, Inc. ("Sutro" or the "Company") (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer therapeutics, today announced new nonclinical data for its folate receptor alpha (FolRα) targeting antibody-drug conjugate (ADC) STRO-002, in an e-poster session, at the American Association for Cancer Research (AACR) Annual Meeting 2022, being held virtually and in New Orleans from April 8-13, 2022.

Sutro Biopharma Presents Nonclinical Data for Antibody-Drug Conjugate STRO-002 at the AACR Annual Meeting 2022

SOUTH SAN FRANCISCO, Calif., April 5, 2022 /PRNewswire/ -- Sutro Biopharma, Inc. ("Sutro" or the "Company") (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer therapeutics, today announced that Bill Newell, Chief Executive Officer, will present at the 21st Annual Needham Virtual Healthcare Conference on Thursday, April 14, 2022, at 3:00 p.m.

Sutro Biopharma to Present at the 21st Annual Needham Virtual Healthcare Conference

SOUTH SAN FRANCISCO, Calif. , March 30, 2022 /PRNewswire/ -- Sutro Biopharma, Inc. ("Sutro" or the "Company") (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer therapeutics, today announced that the company presented on advances with its novel immunostimulatory antibody-drug conjugate (iADC) modality at the 12th Annual World ADC conference taking place virtually and in London, from March 29 through April 1, 2022.

Sutro Biopharma Presented on Advances in Novel Immunostimulatory Antibody-Drug Conjugate Modality at the 12th Annual World ADC

Sutro Biopharma, Inc. (STRO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Sutro Biopharma, Inc. (STRO) Moves 6.4% Higher: Will This Strength Last?

SOUTH SAN FRANCISCO, Calif., March 3, 2022 /PRNewswire/ -- Sutro Biopharma, Inc. ("Sutro" or the "Company") (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer therapeutics, today announced that Bill Newell, Chief Executive Officer, will participate in the Ovarian Cancer Panel at the Cowen 42nd Annual Healthcare Conference on Wednesday, March 9, 2022, at 12:50 p.m.

Sutro Biopharma to Participate in the Cowen 42nd Annual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2022 /PRNewswire/ -- Sutro Biopharma, Inc. ("Sutro" or the "Company") (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer therapeutics, today reported its financial results for the full year 2021, its recent business highlights, and a preview of anticipated select milestones in 2022.

Sutro Biopharma Reports Full Year 2021 Financial Results, Business Highlights, and Anticipated 2022 Milestones

Coeur Mining

Hyster-Yale Materials Handling

Peloton

Ribbon Communications

Boston Beer Company

Wayfair

The contrarian in a lot of people perks up during selloffs like the one we're in right now, but don't let these F-rated stocks tempt you. The post 7 Triple-F-Rated Stocks That Have No Hope in Sight appeared first on InvestorPlace.

7 Triple-F-Rated Stocks That Have No Hope in Sight

New York, New York--(Newsfile Corp. - February 3, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Sutro Biopharma, Inc. ("Sutro" or the "Company") (NASDAQ: STRO). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Sutro and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sutro Biopharma, Inc. - STRO

Atlanta, Georgia--(Newsfile Corp. - January 18, 2022) - Holzer & Holzer, LLC is investigating whether Sutro Biopharma, Inc. ("Sutro" or the "Company") (NASDAQ: STRO) complied with federal securities laws. On January 5, 2022, the Company "provided a clinical update from the Company's ongoing, fully enrolled, dose-expansion Phase 1 study of STRO-002, a folate receptor alpha (FolRα)-targeting antibody-drug conjugate (ADC), for patients with advanced ovarian cancer." Following the clinical update, the Company's stock price fell.If...

SHAREHOLDER ALERT: Investigation of Sutro Biopharma, Inc. Announced by Holzer & Holzer, LLC

The stock price of Sutro Biopharma Inc (NASDAQ: STRO) fell by 27.87% in the most recent trading session. This is why it happened.

Sutro Biopharma Stock (STRO): Why The Price Substantially Fell

The stock price of Sutro Biopharma, Inc. (NASDAQ: STRO) fell by over 29% during intraday trading today. This is why it happened.

Sutro Biopharma Stock (STRO): Why The Price Substantially Fell Today

Phase 1 data for its ovarian cancer candidate was a little disappointing.

News for Sutro Biopharma Inc Stock (STRO)